Basic details of a product, only using MedicinalProductDefinition and no other resources

@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

[a fhir:MedicinalProductDefinition;
  fhir:nodeRole fhir:treeRoot;
  fhir:Resource.id [ fhir:value "equilidem-basics"];
  fhir:DomainResource.text [
     fhir:Narrative.status [ fhir:value "generated" ];
     fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n			<p>\n				<b>\n					Generated Narrative\n				</b>\n			</p>\n			<p>\n				<b>\n					Id\n				</b>\n				: equilidem-basics\n			</p>\n			<p>\n				<b>\n					Identifier\n				</b>\n				: Equilidem25\n			</p>\n			<p>\n				<b>\n					Combined Pharmaceutical Dose Form\n				</b>\n				:\n				<span title=\"Codes: {http://example.org.uk/fhir/dosefom tablet}\">\n					tablet\n				</span>\n			</p>\n			<p>\n				<b>\n					Indication\n				</b>\n				: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class &gt;= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.\n			</p>\n			<p>\n				<b>\n					Legal Status Of Supply\n				</b>\n				:\n				<span title=\"Codes: {http://example.org.uk/fhir/legalstatusofsupply POM}\">\n					Prescription only medicine\n				</span>\n			</p>\n			<p>\n				<b>\n					Classification\n				</b>\n				:\n				<span title=\"Codes: {http://www.whocc.no/atc/example B01A}\">\n					ATC: B01A\n				</span>\n			</p>\n			<p>\n				<b>\n					Ingredient\n				</b>\n				:\n			</p>\n			<ul>\n				<li>\n					<span>\n						Equilidonium Phosphate\n					</span>\n				</li>\n				<li>\n					<span>\n						Calcium Carbonate\n					</span>\n				</li>\n			</ul>\n			<h3>\n				Names\n			</h3>\n			<table class=\"grid\">\n				<tr>\n					<td>\n						-\n					</td>\n					<td>\n						<b>\n							Product Name\n						</b>\n					</td>\n				</tr>\n				<tr>\n					<td>\n						*\n					</td>\n					<td>\n						Equilidem 2.5 mg film-coated tablets\n					</td>\n				</tr>\n			</table>\n			<h3>\n				Cross References\n			</h3>\n			<table class=\"grid\">\n				<tr>\n					<td>\n						-\n					</td>\n					<td>\n						<b>\n							Product\n						</b>\n					</td>\n				</tr>\n				<tr>\n					<td>\n						*\n					</td>\n					<td>\n						Link to generic equivalent\n					</td>\n				</tr>\n			</table>\n			<h3>\n				Manufacturing/Business Operations\n			</h3>\n			<table class=\"grid\">\n				<tr>\n					<td>\n						-\n					</td>\n					<td>\n						<b>\n							Manufacturer\n						</b>\n					</td>\n				</tr>\n				<tr>\n					<td>\n						*\n					</td>\n					<td>\n						<span>\n							EquiliDrugCo Inc.\n						</span>\n					</td>\n				</tr>\n			</table>\n		</div>"
  ];
  fhir:MedicinalProductDefinition.identifier [
     fhir:index 0;
     fhir:Identifier.system [ fhir:value "http://example.org.uk/fhir/product" ];
     fhir:Identifier.value [ fhir:value "Equilidem25" ]
  ];
  fhir:MedicinalProductDefinition.combinedPharmaceuticalDoseForm [
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "http://example.org.uk/fhir/dosefom" ];
       fhir:Coding.code [ fhir:value "tablet" ]
     ]
  ];
  fhir:MedicinalProductDefinition.indication [ fhir:value "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."];
  fhir:MedicinalProductDefinition.legalStatusOfSupply [
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "http://example.org.uk/fhir/legalstatusofsupply" ];
       fhir:Coding.code [ fhir:value "POM" ];
       fhir:Coding.display [ fhir:value "Prescription only medicine" ]
     ]
  ];
  fhir:MedicinalProductDefinition.classification [
     fhir:index 0;
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "http://www.whocc.no/atc/example" ];
       fhir:Coding.code [ fhir:value "B01A" ]
     ]
  ];
  fhir:MedicinalProductDefinition.ingredient [
     fhir:index 0;
     fhir:CodeableConcept.text [ fhir:value "Equilidonium Phosphate" ]
  ], [
     fhir:index 1;
     fhir:CodeableConcept.text [ fhir:value "Calcium Carbonate" ]
  ];
  fhir:MedicinalProductDefinition.name [
     fhir:index 0;
     fhir:MedicinalProductDefinition.name.productName [ fhir:value "Equilidem 2.5 mg film-coated tablets" ]
  ];
  fhir:MedicinalProductDefinition.crossReference [
     fhir:index 0;
     fhir:MedicinalProductDefinition.crossReference.product [
       fhir:CodeableReference.reference [
         fhir:Reference.reference [ fhir:value "MedicinalProductDefinition/genericEquilidonium" ]
       ]
     ]
  ];
  fhir:MedicinalProductDefinition.operation [
     fhir:index 0;
     fhir:MedicinalProductDefinition.operation.organization [
       fhir:index 0;
       fhir:Reference.display [ fhir:value "EquiliDrugCo Inc." ]
     ]
  ]] .

# - ontology header ------------------------------------------------------------

[a owl:Ontology;
  owl:imports fhir:fhir.ttl] .

# -------------------------------------------------------------------------------------